SCENESSE attains breakthrough European Market Authorisation
Filed with ASX · · 3 pages · English
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings CallClinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- US patent for alpha-MSH and analogues
- Patent to assist drug as potential skin cancer preventative
- Clinuvel to evaluate SCENESSE as therapy in vitiligo
- Clinuvel - strategic focus of final regulatory program
- Clinuvel selects leading US manufacturing partner
Later from Clinuvel Pharmaceuticals
- SCENESSE Treatment in Europe
- SCENESSE launched in Europe
- FDA awards SCENESSE Fast Track designation for EPP treatment
- FDA accept SCENESSE clinical data package for NDA submission
- Clinuvel completes combination therapy pre-clinical study
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals